Brooklyn ImmunoTherapeutics Inc. (AMEX:BTX) price on Friday, August 06, fall -0.44% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $11.40.
A look at the stock’s price movement, the close in the last trading session was $11.45, moving within a range at $11.07 and $11.63. Turning to its 52-week performance, $80.67 and $3.04 were the 52-week high and 52-week low respectively. Overall, BTX moved -18.75% over the past month.
Brooklyn ImmunoTherapeutics Inc.’s market cap currently stands at around $514.14 million.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s).
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 0 recommend BTX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BTX’s current price about -1.15% and -20.98% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 43.69, while 7-day volatility ratio is 9.58% and 11.55% in the 30-day chart. Further, Brooklyn ImmunoTherapeutics Inc. (BTX) has a beta value of 4.86, and an average true range (ATR) of 1.31. Analysts have given the company’s stock an average 52-week price target of $11.00, forecast between a low of $11.00 and high of $11.00. Looking at the price targets, the low is 3.51% off current price level while to achieve the yearly target high, price needs to move 3.51%. Nonetheless, investors will most likely welcome a 3.51% jump to $11.00 which is the analysts’ median price.
In the market, a comparison of Brooklyn ImmunoTherapeutics Inc. (BTX) and its peers suggest the former has performed considerably weaker. Data shows BTX’s intraday price has changed -0.44% in last session and 168.87% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.17% and 0.41% respectively in the last trading.
If we refocus on Brooklyn ImmunoTherapeutics Inc. (AMEX:BTX), historical trading data shows that trading volumes averaged 1.1 million over the past 10 days and 4.28 million over the past 3 months. The company’s latest data on shares outstanding shows there are 27.80 million shares.
The 13.80% of Brooklyn ImmunoTherapeutics Inc.’s shares are in the hands of company insiders while institutional holders own 1.20% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.67 million on May 27, 2021, giving us a short ratio of 0.05. The data shows that as of May 27, 2021 short interest in Brooklyn ImmunoTherapeutics Inc. (BTX) stood at 1.56% of shares outstanding, with shares short falling to 0.94 million registered in Apr 29, 2021. Current price change has pushed the stock 154.46% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BTX stock continues to rise going into the next quarter.